GLP-1 medications and heart health: what the cardiovascular evidence actually shows

When GLP-1 medications entered the mainstream conversation, they were framed almost entirely as weight-loss drugs. That framing is incomplete. The drugs that were originally developed to lower blood sugar in type 2 diabetes -- and later found to drive substantial weight loss -- have now accumulated one of the most robust cardiovascular outcome datasets of any drug class in recent decades. A 2025 systematic review and network meta-analysis in PubMed synthesized that evidence across multiple agents and confirmed what several large individual trials had already suggested: GLP-1 receptor agonists meaningfully reduce the risk of major adverse cardiovascular events in high-risk patients (https://pubmed.ncbi.nlm.nih.gov/42219271/).

If you are managing type 2 diabetes, overweight, or both, this evidence matters more than any number on a scale. Here is what the research actually shows -- and what it does not.

What GLP-1 drugs are and why the heart connection is not a coincidence

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. It tells your pancreas to release insulin, tells your liver to slow glucose production, and signals your brain that you are full. GLP-1 receptor agonists are synthetic versions that stay active far longer than the natural hormone -- long enough to change the metabolic environment meaningfully over days and weeks.

The heart connection was not originally the selling point. It became unavoidable when the FDA, after a series of cardiovascular safety scares with older diabetes drugs, began requiring that all new diabetes medications prove they did not increase cardiovascular risk before approval. Manufacturers had to run large, long cardiovascular outcome trials (CVOTs). Those trials did not just prove safety. Several of them proved benefit.

GLP-1 receptors are present in heart muscle, blood vessels, and the kidney. Research has shown that GLP-1 signaling appears to reduce inflammation in vessel walls, lower blood pressure modestly, improve endothelial function, and reduce oxidative stress -- effects that are not simply downstream of weight loss (https://pubmed.ncbi.nlm.nih.gov/26748988/). This is a drug class that appears to act on the cardiovascular system through multiple mechanisms simultaneously.

The trial-by-trial story: what the evidence actually shows

The cardiovascular outcome trial era for GLP-1 drugs began around 2015 and has since produced a consistent body of evidence -- with some important nuances between agents.

Liraglutide (Victoza) was the first to show a statistically significant cardiovascular benefit. In the LEADER trial, people with type 2 diabetes and high cardiovascular risk who took liraglutide had a 13% lower rate of MACE (major adverse cardiovascular events -- defined as heart attack, stroke, or cardiovascular death) compared with placebo at a median follow-up of 3.8 years (https://www.nejm.org/doi/full/10.1056/NEJMoa1603827). That is a meaningful reduction in a population where these events are common.

Semaglutide (Ozempic/Wegovy) followed with the SUSTAIN-6 trial, which showed a 26% reduction in MACE in a similar high-risk population (https://www.nejm.org/doi/full/10.1056/NEJMoa1607141). Most of the benefit came from a reduction in non-fatal stroke -- a finding that has held up across subsequent analyses. The injectable once-weekly form (Ozempic) is approved for cardiovascular risk reduction in type 2 diabetes; the higher-dose weekly form (Wegovy) received a separate indication for cardiovascular risk reduction in people with obesity and established cardiovascular disease after the SELECT trial showed a 20% relative risk reduction in MACE in non-diabetic patients with obesity (https://www.nejm.org/doi/full/10.1056/NEJMoa2307563). That SELECT finding was significant because it established that the cardiovascular benefit was not purely a diabetes drug story -- it extended to people with obesity and heart disease regardless of glucose metabolism.

Dulaglutide (Trulicity) showed a 12% reduction in MACE in the REWIND trial, which notably included a broader population -- including people without established cardiovascular disease, just high risk (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31149-3/fulltext). This was the first trial to suggest benefit in primary prevention, though the evidence there is weaker and still evolving.

Albiglutide (Tanzeum) showed a 22% MACE reduction in the Harmony Outcomes trial before the drug was withdrawn from the market for commercial reasons unrelated to safety (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32261-X/fulltext).

Exenatide (Bydureon) and lixisenatide (Adlyxin) showed cardiovascular neutrality -- they did not increase risk, but did not significantly reduce it either, in the EXSCEL and ELIXA trials (https://www.nejm.org/doi/full/10.1056/NEJMoa1612917; https://www.nejm.org/doi/full/10.1056/NEJMoa1509225). This matters because it tells us the cardiovascular benefit is not a class effect in the simple sense -- structure, dosing, and molecule-specific properties appear to influence the outcome.

The 2025 network meta-analysis: putting it all together

A network meta-analysis published in 2025 synthesized the full body of cardiovascular outcome trial data across GLP-1 agents and found that the agents with the strongest evidence -- particularly semaglutide and liraglutide -- consistently reduced MACE, cardiovascular death, and all-cause mortality in high-risk populations (https://pubmed.ncbi.nlm.nih.gov/42219271/). The analysis also highlighted that reductions in heart failure hospitalization were more variable across agents, with some drugs showing clearer heart failure benefit than others.

For clinical decision-making, what this means is that drug selection within the GLP-1 class should be informed by the individual's primary risk -- whether that is stroke, heart attack, heart failure, or kidney disease -- and not just by weight-loss efficacy or cost. The 2024 American Diabetes Association Standards of Care now recommend GLP-1 receptor agonists with proven cardiovascular benefit as a preferred add-on therapy in people with type 2 diabetes and established cardiovascular disease, independent of HbA1c control (https://diabetesjournals.org/care/article/47/Supplement_1/S1/153954).

Beyond MACE: the wider cardiovascular picture

The cardiovascular story does not begin and end with heart attacks and strokes. A growing body of evidence -- synthesized in a 2025 review of multisystem benefits from obesity medications -- shows that GLP-1 receptor agonists also reduce blood pressure by roughly 3 to 5 mmHg systolic on average, modestly improve lipid profiles, reduce markers of systemic inflammation, slow the progression of diabetic kidney disease, and may reduce the risk of atrial fibrillation (https://pubmed.ncbi.nlm.nih.gov/42208956/).

These effects compound. Someone who lowers their blood pressure, loses 10 to 15% of body weight, improves their HbA1c, and reduces arterial inflammation simultaneously is not simply in a better-looking lab panel -- they are in a materially different cardiovascular risk category. That is what these drugs can do in the right patient, managed properly.

If you are also working on physical activity -- and the American Heart Association's 2025 scientific statement makes clear that structured exercise remains an important complement to any medical obesity treatment (https://pubmed.ncbi.nlm.nih.gov/42220241/) -- the combination is more powerful than either approach alone. We address that tradeoff in more detail in our post on breaking a GLP-1 weight-loss plateau.

What the evidence does not yet answer

Honesty matters here. The cardiovascular outcome trials were conducted almost entirely in people with type 2 diabetes and established or high-risk cardiovascular disease. Extrapolating those results to younger, lower-risk patients who are using GLP-1 drugs primarily for weight loss -- without diabetes or known heart disease -- requires more caution. The SELECT trial was a step toward answering that question for people with obesity and cardiovascular disease, but primary prevention data in lower-risk populations without diabetes is still limited.

The question of what happens when someone stops the medication is also unresolved. Weight typically returns after discontinuation, and it is reasonable to wonder whether cardiovascular risk returns with it. Some data suggest the cardiovascular benefit during the treatment period is real regardless, but long-term off-treatment follow-up data are sparse.

Finally, the majority of large trials used injectable once-weekly formulations. Oral semaglutide (Rybelsus) has cardiovascular data from the SOUL trial, but oral tirzepatide and other newer oral agents are still in earlier cardiovascular evaluation stages. Our GLP-1 comprehensive guide covers the emerging oral agent landscape in more detail.

How we think about this clinically at NBH

Dr. Jezwah Harris (NP, JD, MBA, FNP-BC, MEP-C) approaches GLP-1 prescribing as a cardiovascular decision, not just a weight-loss decision. That means we start with a full metabolic and cardiovascular risk assessment -- blood pressure, fasting glucose, HbA1c, lipids, kidney function, body composition, and a complete medication review -- before the first dose. We also ask about your goals. Are you trying to lower your A1c? Reduce your ten-year cardiovascular risk score? Lose weight to come off blood pressure medication? The answer shapes the drug choice, the target dose, and the monitoring plan.

We re-check labs at six weeks, at three months, and at regular intervals thereafter. If you are also on antihypertensives or diabetes medications, doses often need to be adjusted downward as the GLP-1 medication takes effect -- and that adjustment requires a clinician who is actually following your numbers. A protocol that stops at the prescription pad is not a protocol.

We also tell you when a GLP-1 drug is not the right tool. If your cardiovascular risk is low, your glucose is normal, and your weight is modestly elevated, the risk-benefit calculation is different than it is for someone with a prior heart attack and an A1c of 9. We name that tradeoff honestly rather than defaulting to the prescription that is currently popular.

If you want to understand where you stand -- your actual cardiovascular risk number, what your labs are telling you, and whether a GLP-1 medication belongs in your plan -- book a new-patient visit at our medical weight loss program. We will review everything, explain the evidence, and give you a real opinion. You can also reach us at (786) 744-5152.

The science here is genuinely exciting. But it is most useful when it is applied carefully, by someone who knows your chart.